Monthly file
May 2026
Every report in the May 2026 file of The Peptide Gazette: 3 reports built on primary documents dated that month. A report is filed under the date of the document it stands on, never the date the page was generated.
-
FDA proposes not to add semaglutide, tirzepatide or liraglutide to the 503B bulks list
The notice names three bulk drug substances the agency has considered and proposes to leave off the list that outsourcing facilities draw on when compounding.
-
Comment sought on the 503A and 503B compounding information collection
The agency opened a 60-day comment period on the information collection relating to human drug compounding under sections 503A and 503B of the Act.
-
Lupin recalls liraglutide pen injectors after particulate found in a cartridge
The nationwide Class II recall covers 217,621 pen injectors. The enforcement record gives the reason as presence of particulate matter, described as a white thread-like structure in the cartridge.